Clinical breast cancer最新文献

{"title":"Impact of Anti-Estrogen Therapy on Early Cardiovascular Referrals, Tests and Medications in Premenopausal Women with Operable Breast Cancer","authors":"Emily Douglas ,&nbsp;Beverly Levine ,&nbsp;Ahmer Ansari ,&nbsp;Katherine Ansley ,&nbsp;Susan Melin ,&nbsp;Carolyn J. Park ,&nbsp;Karl Richardson ,&nbsp;Sarah Hatcher ,&nbsp;Ralph B. D'Agostino Jr. ,&nbsp;Jennifer H. Jordan ,&nbsp;Alexandra Thomas","doi":"10.1016/j.clbc.2024.02.006","DOIUrl":"10.1016/j.clbc.2024.02.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Premenopausal women with high-risk hormone receptor (HR)-positive breast cancer often receive ovarian function suppression (OFS) and anti-estrogen therapy which induces near complete estrogen deprivation (NCED). This treatment improves recurrence-free survival but may increase cardiovascular risk. We sought to identify patterns of cardiovascular care and outcomes in premenopausal women with operable breast cancer.</p></div><div><h3>Methods</h3><p>Premenopausal women ≤ 50 years of age with stage I-III HR-positive or triple negative breast cancer (TNBC) were identified by retrospective review. We categorized women into 3 groups based on anti-estrogen therapy approach: NCED (HR + OFS), anti-estrogen therapy without OFS (HRnoOFS), and no anti-estrogen therapy (TNBC). Baseline characteristics, post-diagnosis cardiovascular events and cardiovascular actions (tests, referrals and medications) were recorded. Categorical variables were compared among the groups using chi-square and Fisher's exact tests; continuous outcomes were compared using ANOVA.</p></div><div><h3>Results</h3><p>82, 83, and 52 women were identified in the HR + OFS, HRnoOFS, and TNBC groups respectively; mean follow-up was 5.0 years. Mean number of cardiovascular actions per year were highest in the HR + OFS group compared with HRnoOFS and TNBC groups (0.35 vs. 0.20 and 0.27, respectively; <em>P</em> = .036). The HR + OFS group had significantly more referrals and tests per year than the other groups. Cardiovascular medication initiation did not differ among groups.</p></div><div><h3>Conclusions</h3><p>In this early follow-up period, there were meaningful numbers of cardiovascular actions, with women on NCED experiencing the most per year. Future work should seek to further understand the impact of anti-estrogen therapy on the cardiovascular health of premenopausal women and test strategies to mitigate cardiotoxicity.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139917806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nipple Reconstruction Using the “Arrow Flap” Technique: Outcomes and Patients Satisfaction","authors":"Vito Cazzato ,&nbsp;Chiara Stocco ,&nbsp;Alessandro Scian ,&nbsp;Luigi Bonat Guarini ,&nbsp;Giulia Benedetta Sidoti ,&nbsp;Nadia Renzi ,&nbsp;Vittorio Ramella ,&nbsp;Giovanni Papa","doi":"10.1016/j.clbc.2024.01.011","DOIUrl":"10.1016/j.clbc.2024.01.011","url":null,"abstract":"<div><h3>Introduction</h3><p>Skin-sparing mastectomy (SSM) entails complete removal of the breast tissue and the nipple and areola complex (NAC) with preservation of as much of the overlying skin as possible. The preservation of the natural skin envelope during SSM improves the aesthetic outcome of immediate breast reconstruction, but the lack of NAC determines that the reconstructed breast remains anatomically incomplete with not always satisfactory final results. For this purpose, the aim of the present study was to investigate and evaluate the impact of nipple reconstruction after skin sparing and skin reducing mastectomy on the patients’ perception and intimate life.</p></div><div><h3>Materials and Method</h3><p>This was a comparative single-center prospective study that involved 42 patients underwent NAC reconstruction after SSM. A pre- and postoperative quality-of-life and psychological questionnaires Breast-Q questionnaire (Breast Conserving therapy module) were given to all the patients before the surgery and 6 months after. The statistical analysis with chi-square test was performed.</p></div><div><h3>Results</h3><p>After 6 months a prevalence of patients reported to be very satisfied in regard to shape, appearance, naturalness, projection, position and symmetry. The study shows an overall improvement in all the psychological items analyzed with statistically significant difference regarding: “patient's satisfaction,” “self-confidence,” “appearance of the breast.”</p></div><div><h3>Conclusion</h3><p>The authors believe that the NAC reconstruction has useful functional and aesthetic results particularly appreciated by patients who feel demoralized after breast demolition surgery.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1526820924000211/pdfft?md5=d2c071a97c3bee7290c5fa460649193b&pid=1-s2.0-S1526820924000211-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139555651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer","authors":"Muheng Liao ,&nbsp;Jace Webster ,&nbsp;Emily M. Coonrod ,&nbsp;Katherine N. Weilbaecher ,&nbsp;Christopher A. Maher ,&nbsp;Nicole M. White","doi":"10.1016/j.clbc.2024.02.007","DOIUrl":"10.1016/j.clbc.2024.02.007","url":null,"abstract":"<div><h3>Background</h3><p>Breast cancer, particularly the estrogen receptor positive (ER+) subtype, remains a leading cause of cancer-related death among women. Endocrine therapy is the most effective treatment for ER+ breast cancer; however, the development of resistance presents a significant challenge. This study explored the role of the <em>breast cancer antiestrogen resistance 4</em> (<em>BCAR4</em>) gene as a potential driver of resistance and a pivotal biomarker in breast cancer.</p></div><div><h3>Patients and Methods</h3><p>The researchers undertook a comprehensive analysis of 1743 patients spanning 6 independent cohorts. They examined the association of <em>BCAR4</em> expression with patient outcomes across all breast cancer types and the PAM50 molecular subtypes. The relationship between elevated <em>BCAR4</em> expression and resistance to endocrine therapy including AIs, the prevailing standard-of-care for endocrine therapy, was also investigated.</p></div><div><h3>Results</h3><p>This meta-analysis corroborated the link between <em>BCAR4</em> expression and adverse outcomes as well as resistance to endocrine therapy in breast cancer. Notably, <em>BCAR4</em> expression is clinically significant in luminal A and B subtypes. Additionally, an association between <em>BCAR4</em> expression and resistance to AI treatment was discerned.</p></div><div><h3>Conclusion</h3><p>This study expands on previous findings by demonstrating that <em>BCAR4</em> expression is associated with resistance to newer therapies. The identification of patients with intrinsic resistance to hormone therapy is crucial to avoid ineffective treatment strategies. These findings contribute to our understanding of endocrine therapy resistance in breast cancer and could potentially guide the development of more effective treatment strategies.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139917814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of miRNAs on the Efficacy of Tamoxifen in Breast Cancer Treatment: A Systematic Review","authors":"Nima Nikbin Kavishahi ,&nbsp;Aryan Rezaee ,&nbsp;Sara Jalalian","doi":"10.1016/j.clbc.2024.01.015","DOIUrl":"10.1016/j.clbc.2024.01.015","url":null,"abstract":"<div><p>Seventy percent of breast cancer patients have an active estrogen receptor. Tamoxifen interferes with estrogen's ability to bind to cancer cells. The most challenging aspect of tamoxifen, however, is that breast cancer cells become resistant to its effects. Some studies have shown that alterations in miRNA expression contribute significantly to drug resistance in breast cancer. Therefore, the present systematic review aims to investigate miRNAs that significantly influence the response to tamoxifen treatment. The present study follows the PRISMA instructions. The Web of Science, PubMed, and Scopus databases were searched to retrieve English articles. The searches were conducted up to September 11, 2022. The search strategy included the terms “Tamoxifen”, “Breast Neoplasm”, and “MicroRNA”. The inclusion criteria of this study are English, original, and experimental studies investigating miRNAs that are effective in the treatment efficacy of tamoxifen. A total of 565 articles were retrieved. After screening, 75 studies met our inclusion criteria. This systematic review study examined 105 miRNAs, of which 44 have a positive effect, and 47 miRNAs inhibit tamoxifen function. Fourteen miRNAs have a controversial effect, ie, some studies show positive and negative effects. The study of miRNAs affecting tamoxifen function in breast cancer patients may facilitate the identification of individuals at higher risk of disease recurrence. Conversely, it can potentially utilize appropriate interventions to defeat drug resistance effectively.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139584778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of Omitting Sentinel Lymph Node Biopsy in an Under-screened Cohort of Breast Cancer Patients With a Premastectomy Diagnosis of Ductal Carcinoma In Situ","authors":"Jinnie Pang ,&nbsp;Zhiyan Yan ,&nbsp;Qing Ting Tan ,&nbsp;John C. Allen ,&nbsp;Mingjia Wang ,&nbsp;Geok Hoon Lim","doi":"10.1016/j.clbc.2024.02.002","DOIUrl":"10.1016/j.clbc.2024.02.002","url":null,"abstract":"<div><h3>Background</h3><p>Nodal involvement in ductal carcinoma in situ (DCIS) is rare. In patients with DCIS diagnosis prior to mastectomy, a sentinel lymph node biopsy (SLNB) is usually performed during mastectomy, to avoid the risk of reoperation and the non-identification of SLN subsequently, should there be an upgrade to invasive cancer. We aimed to study the feasibility of omitting SLNB in an under-screened cohort, with mostly symptomatic patients and DCIS diagnosis before mastectomy, by determining the upgrade rate to invasive cancer/ DCIS microinvasion (DCISM) and its associated risk factors.</p></div><div><h3>Methods</h3><p>Patients with pure DCIS diagnosis premastectomy were reviewed retrospectively. Patients with known DCISM or invasive cancer before mastectomy and bilateral cancers were excluded. Patients’ demographics, radiological and pathological data premastectomy were analyzed.</p></div><div><h3>Results</h3><p>A total of 189 patients were included. The mean age was 53.8 (range: 29-85) years old. About 64.4% presented with symptoms. 36.0% and 15.3% upgraded to invasive cancer and DCISM on mastectomy respectively. Palpable tumor (<em>P</em> = .0036), large size on ultrasound (<em>P</em> = .0283), tumor seen on mammogram and ultrasound (<em>P</em> = .0082), ultrasound-guided biopsy (<em>P</em> &lt; .0001), high-grade DCIS on biopsy (<em>P</em> = .0350) and no open biopsy/lumpectomy before mastectomy (<em>P</em> &lt; .0001) were associated with the upgrade, with the latter factor remaining significant after multivariable analysis. Nodal involvement was 8.47% and was associated with invasive cancer (<em>P</em> &lt; .0001).</p></div><div><h3>Conclusion</h3><p>In a cohort who had DCIS diagnosis before mastectomy and were mostly symptomatic, the upgrade rate was 51.3%. Despite the high upgrade rate, nodal involvement remained comparable. Risk factors could select patients for omission of upfront SLNB, with a delayed SLNB planned if needed.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139689092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma","authors":"Xiao Huang ,&nbsp;Sarah A. Anderson ,&nbsp;Gene P. Siegal ,&nbsp;Shi Wei ,&nbsp;Shanrun Liu ,&nbsp;Jingyun Yang ,&nbsp;Puentes Roisin ,&nbsp;J. Taylor Pickens ,&nbsp;Lei Huo ,&nbsp;Aysegul A. Sahin ,&nbsp;Carlos Prieto Granada ,&nbsp;Shuojun Chen","doi":"10.1016/j.clbc.2024.02.010","DOIUrl":"10.1016/j.clbc.2024.02.010","url":null,"abstract":"<div><h3>Introduction</h3><p>PD-L1 immunohistochemistry (IHC) is being used as a predictive marker of the benefit derived from immunotherapy in several cancer types, including breast cancer. However, the insight gleaned of the prognostic and predictive value of PD-L1 status and its correlation with molecular characteristics during breast cancer progression remains limited.</p></div><div><h3>Methods</h3><p>We performed an PD-L1 (22C3) assay in pre-treatment primary and metastatic tumor sections from 33 patients with breast carcinoma, matched for post neoadjuvant chemotherapy (p-NACT). PD-L1 expression was evaluated using 3 scoring methods: immune cell (IC) and tumor cell (TC) with a 1% as the cutoff value, and combined positive scores (CPS) with a 1 as the cutoff value. Twenty-two samples from 11 patients had successful fluorescence in situ hybridization (FISH)-based molecular data available for analysis.</p></div><div><h3>Results</h3><p>In the 33 pre-treatment primary tumors, PD-L1 IC, TC, and CPS showed positive correlation with stromal tumor infiltrate lymphocytes (sTIL), histological grade 3, and triple negative breast carcinoma (TNBC). In the matched metastatic tumors, only PD-L1 IC showed a positive correlation with sTIL. The primary tumors showed a higher PD-L1 expression than the matched metastatic tumors by IC and CPS. Negative to positive conversion by CPS was identified in the metastatic tumors from lung, pleura and liver. p-NACT tumors also showed a trend of lower PD-L1 expression compared to the pre-treatment tumors. Six patients had matched samples for molecular and PD-L1 comparison, and none of them showed consistent gene alterations or PD-L1 expression among the primary, p-NACT and metastatic tumors.</p></div><div><h3>Conclusion</h3><p>Our study showed a decrease in PD-L1 expression and disconnected molecular features during breast cancer progression. Repeating PD-L1 IHC testing could be considered in some specific metastatic sites if primary tumors were negative. Further studies are needed to identify other predictive factors for immune checkpoint inhibitor (ICI) therapy in patients with breast carcinoma.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139917776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates in the Surgical Management of Benign and High-Risk Breast Lesions","authors":"Chelsea Marin ,&nbsp;Anna Weiss ,&nbsp;Jessica C. Gooch","doi":"10.1016/j.clbc.2023.12.008","DOIUrl":"10.1016/j.clbc.2023.12.008","url":null,"abstract":"<div><p>Benign breast disease (BBD) is a heterogenous group of lesions often classified as nonproliferative or proliferative, with the latter group further categorized based on the presence of atypia. Although nonproliferative lesions are more common, the risk of breast cancer is elevated in women with proliferative lesions. Historically, the majority of proliferative lesions were excised due to concern for future and/or concomitant breast cancer at the site of the index lesion. However, contemporary data suggest that the risk of cancer associated with various proliferative lesions may be lower than previously thought, and management of BBD has become more nuanced. In this review, we will focus on recent updates in the management of a select group of benign and high-risk lesions.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139016301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: “Diagnostic Delays in Breast Cancer Among Young Women: An Emphasis on Healthcare Providers” by Costa et al.","authors":"Omobolade Sonola","doi":"10.1016/j.clbc.2024.01.023","DOIUrl":"10.1016/j.clbc.2024.01.023","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139818263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Assessment of Radial Scars on Core Needle Biopsy in Patients with or without Breast Cancer: Upgrade Rate and Implications on Management","authors":"Arith Reyes ,&nbsp;Luona Sun ,&nbsp;Richard Ha ,&nbsp;Elise Desperito ,&nbsp;Marc Brown ,&nbsp;Mark A. Francescone ,&nbsp;Stacy Ugras ,&nbsp;Lisa Wiechmann ,&nbsp;Roshni Rao ,&nbsp;Bret Taback","doi":"10.1016/j.clbc.2024.01.020","DOIUrl":"10.1016/j.clbc.2024.01.020","url":null,"abstract":"<div><h3>Background</h3><p>Radial scars/radial sclerosing lesions (RS) are benign breast lesions identified on core needle biopsy (CNB) which can upgrade to malignancy at excision. There is limited data on RS detection and upgrade rates with more sensitive imaging such as magnetic resonance imaging (MRI) and none during their detection for breast cancer workup and its implication on patient treatment decisions.</p></div><div><h3>Methods</h3><p>A retrospective institutional study of RS diagnosed on CNB between January 2008 and December 2017 was conducted. Clinicopathologic and radiologic features of RS, patient treatment decisions, upgrade rates and long-term follow-up were examined.</p></div><div><h3>Results</h3><p>We identified 133 patients with RS on CNB, of whom 106 opted for surgery for an upgrade rate to malignancy of 1.9%, 2 patients. Radial scar was diagnosed on mammogram in 60%, MRI in 25% and ultrasound in 15% of patients. In this cohort, 32 patients had their RS detected during breast cancer workup (coexistent group) and they were more likely to have their radial scar detected by MRI (60% vs. 14%, <em>P</em> &lt; .001) and undergo more extensive surgery (94% vs. 75%, <em>P</em> = .02). Among the 27 patients electing observation of their RS, only one (3.7%) developed breast cancer.</p></div><div><h3>Conclusions</h3><p>Our results show an extremely low upgrade rate to malignancy of RS, regardless if there is coexisting breast cancer elsewhere. Despite this, RS still prompted more extensive surgical excisions. The findings do not support excision of RS even among breast cancer patients when identified at a separate site from their cancer.</p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139668755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on Management of Ductal Carcinoma in Situ","authors":"Joanna T. Buchheit ,&nbsp;David Schacht ,&nbsp;Swati A. Kulkarni","doi":"10.1016/j.clbc.2023.12.010","DOIUrl":"10.1016/j.clbc.2023.12.010","url":null,"abstract":"<div><p><span>Ductal carcinoma in situ<span> (DCIS) represents 18% to 25% of all diagnosed breast cancers, and is a noninvasive, nonobligate precursor lesion to invasive cancer. The diagnosis of DCIS represents a wide range of disease, including lesions with both low and high risk of progression to invasive cancer and recurrence. Over the past decade, research on the topic of DCIS has focused on the possibility of tailoring treatment for patients according to their risk for progression and recurrence, which is based on clinicopathologic, biomolecular and </span></span>genetic factors<span>. These efforts are ongoing, with recently completed and continuing clinical trials<span> spanning the continuum of cancer care. We conducted a review to identify recent advances on the topic of diagnosis, risk stratification<span> and management of DCIS. While novel imaging techniques<span> have increased the rate of DCIS diagnosis, questions persist regarding the optimal management of lesions that would not be identified with conventional methods. Additionally, among trials investigating the potential for omission of surgery and use of active surveillance, 2 trials have completed accrual and 2 clinical trials are continuing to enroll patients. Identification of novel genetic patterns is expanding our potential for risk stratification and aiding our ability to de-escalate radiation and systemic therapies for DCIS. These advances provide hope for tailoring of DCIS treatment in the near future.</span></span></span></span></p></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139053317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}